– THRIVE-2 world section 3 medical trial evaluated efficacy and security of veligrotug in sufferers with continual thyroid eye illness (TED) –
– Convention name and webcast to be held Monday, December 16, at 8:00 a.m. ET –
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical firm centered on discovering and creating potential best-in-class medicines for critical and uncommon illnesses, right now introduced plans to host a convention name and webcast to report topline information for the THRIVE-2 section 3 medical trial, evaluating veligrotug in continual TED, on Monday, December 16, 2024 at 8:00am ET.
Convention name and webcast info
The webcast may be accessed beneath Occasions and Displays on the Traders part of the Viridian web site at viridiantherapeutics.com. To take part within the convention name, please dial 800-715-9871 (home) or 646-307-1963 (worldwide) and reference code 9934051. A replay of the webcast can be out there following the completion of the occasion.
About Viridian Therapeutics
Viridian is a biopharmaceutical firm centered on engineering and creating potential best-in-class medicines for sufferers with critical and uncommon illnesses. Viridian’s experience in antibody discovery and protein engineering allows the event of differentiated therapeutic candidates for beforehand validated drug targets in commercially established illness areas.
Viridian is advancing a number of candidates within the clinic for the remedy of sufferers with thyroid eye illness (TED). The corporate is conducting a pivotal program for veligrotug (VRDN-001), together with two world section 3 medical trials (THRIVE and THRIVE-2), to judge its efficacy and security in sufferers with lively and continual TED. Viridian can be advancing VRDN-003 as a possible best-in-class subcutaneous remedy for the remedy of TED, together with two ongoing world section 3 pivotal medical trials, REVEAL-1 and REVEAL-2, to judge the efficacy and security of VRDN-003 in sufferers with lively and continual TED.
Along with its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, together with VRDN-006 and VRDN-008, which has the potential to be developed in a number of autoimmune illnesses.
Viridian relies in Waltham, Massachusetts. For extra info, please go to www.viridiantherapeutics.com. Comply with Viridian on LinkedIn and X.
Ahead Wanting Statements
This press launch comprises forward-looking statements inside the which means of the Personal Securities Litigation Reform Act of 1995. These statements could also be recognized by means of phrases akin to, however not restricted to, anticipate, imagine, proceed, may, estimate, count on, intend, could, may, on monitor, plan, potential, predict, mission, design, ought to, goal, will, or would or different comparable phrases or expressions that concern our expectations, plans and intentions. Ahead-looking statements are neither historic information nor assurances of future efficiency. As a substitute, they’re based mostly on our present beliefs, expectations, and assumptions. Ahead-looking statements embody, with out limitation, statements concerning: preclinical and medical growth of Viridian’s product candidates veligrotug (previously VRDN-001), VRDN-003, VRDN-006 and VRDN-008; Viridian’s product candidates doubtlessly being best-in-class; and the potential for Viridian’s product candidates to be developed in a number of autoimmune illnesses.
New dangers and uncertainties could emerge once in a while, and it isn’t potential to foretell all dangers and uncertainties. No representations or warranties (expressed or implied) are made in regards to the accuracy of any such forward-looking statements. Such forward-looking statements are topic to quite a few materials dangers and uncertainties together with however not restricted to the potential utility, efficacy, efficiency, security, medical advantages, medical response and comfort of Viridian’s product candidates and people dangers set forth beneath the caption Danger Components in our most up-to-date quarterly report on Kind 10-Q filed with the Securities and Alternate Fee (SEC) on November 12, 2024 and different subsequent disclosure paperwork filed with the SEC. Any forward-looking assertion speaks solely as of the date on which it was made. Neither the corporate, nor its associates, advisors, or representatives, undertake any obligation to publicly replace or revise any forward-looking assertion, whether or not because of new info, future occasions or in any other case, besides as required by legislation. These forward-looking statements shouldn’t be relied upon as representing the corporate’s views as of any date subsequent to the date hereof.
View supply model on businesswire.com: https://www.businesswire.com/information/dwelling/20241213672239/en/
Anabel Chan, 617-458-8725
Vice President, Investor Relations & Communications
IR@viridiantherapeutics.com
Louisa Stone, 617-272-4604
Supervisor, Investor Relations
IR@viridiantherapeutics.com
Supply: Viridian Therapeutics, Inc.
